Identification

Name
Pazopanib
Accession Number
DB06589
Type
Small Molecule
Groups
Approved
Description

Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

Structure
Thumb
Synonyms
  • GW 78603
  • Pazopanibum
External IDs
GW-786034 / GW786034
Product Ingredients
IngredientUNIICASInChI Key
Pazopanib Hydrochloride33Y9ANM545635702-64-6MQHIQUBXFFAOMK-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
VotrientTablet400 mgOralNovartisNot applicableNot applicableCanada
VotrientTablet200 mgOralNovartis2010-08-13Not applicableCanada
VotrientTablet, film coated200 mgOralNovartis Europharm Limited2010-06-14Not applicableEu
VotrientTablet, film coated200 mg/1OralNovartis2016-07-12Not applicableUs
VotrientTablet, film coated400 mgOralNovartis Europharm Limited2010-06-14Not applicableEu
VotrientTablet, film coated200 mgOralNovartis Europharm Limited2010-06-14Not applicableEu
VotrientTablet, film coated200 mg/1OralGlaxosmithkline Inc2009-10-192017-11-30Us
VotrientTablet, film coated400 mgOralNovartis Europharm Limited2010-06-14Not applicableEu
Categories
UNII
7RN5DR86CK
CAS number
444731-52-6
Weight
Average: 437.518
Monoisotopic: 437.163393705
Chemical Formula
C21H23N7O2S
InChI Key
CUIHSIWYWATEQL-UHFFFAOYSA-N
InChI
InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)
IUPAC Name
5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzene-1-sulfonamide
SMILES
CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1

Pharmacology

Indication

Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)

Associated Conditions
Pharmacodynamics

Pazopanib is a synthetic indazolylpyrimidine and reaches steady state concentrations of >15 μg/ml. This concentration is high enough to observe maximal inhibition of VEGFR2 phosphorylation and some anti-tumour activity (concentration required to inhibit receptors is 0.01 - 0.084 μmol/L). A reduction in tumour blood flow, increased tumour apoptosis, inhibition of tumour growth, reduction in tumour interstitial fluid pressure, and hypoxia in cancer cells can be observed in patients receiving treatment.

Mechanism of action

Pazopanib is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived growth factor receptor-beta, and c-kit. These receptor targets are part of the angiogenesis pathway that facilitates the formation of tumour blood vessel for tumour survival and growth.

TargetActionsOrganism
AVascular endothelial growth factor receptor 1
inhibitor
Human
AVascular endothelial growth factor receptor 2
inhibitor
Human
AVascular endothelial growth factor receptor 3Not AvailableHuman
APlatelet-derived growth factor receptor alpha
inhibitor
Human
APlatelet-derived growth factor receptor beta
inhibitor
Human
AMast/stem cell growth factor receptor Kit
inhibitor
Human
UFibroblast growth factor receptor 3
inhibitor
Human
UTyrosine-protein kinase ITK/TSK
inhibitor
Human
UFibroblast growth factor 1
inhibitor
Human
USH2B adapter protein 3
inhibitor
Human
Absorption

Absorption of pazopanib in cancer patients is slow and incomplete. In patients with solid tumour, over a dose range of 50-2000 mg, absorption is nonlinear. Significant accumulation of pazopanib can also be observed in patients receiving 800 mg once daily for 22 days. Crushing tablets may increase exposure (increase in Cmax and AUC, while Tmax decreases by 2 hours). Bioavailability, oral tablet 800 mg, cancer patient = 21%; Bioavailability may be low due to incomplete absorption from the gastrointestinal tract. The major circulating component of the drug in the systemic is pazopanib, and not its metabolites. Mean maximum plasma concentration= 58.1 µg/mL; Mean AUC= 1037 µg · h/mL;

Volume of distribution

Vd steady state, IV administration 5 mg, cancer patient = 11.1 L (range of 9.15 - 13.4)

Protein binding

>99% protein bound, independent of concentrations over a range of 10-100 μg/mL.

Metabolism

Metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8. Metabolites are less active than pazopanib (10 to 20-fold less active). Three of its metabolites can be observed in the systemic and account for <10% of plasma radioactivity.

Route of elimination

Primarily excreted via feces (82.2%) and to a negligible extent via urine (<4%) in cancer patients. Most of the administered dose is excreted unchanged. Approximately 10% of dose are oxidative metabolites and are mostly eliminated via the feces.

Half life

35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.

Clearance

CL, cancer patient, IV administration 5 mg = 4mL/min Half of the absorbed dose is cleared via oxidative metabolism.

Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
UDP-glucuronosyltransferase 1-1UGT1A1*28(TA;TA)TA pair insertionADR Directly StudiedThe presence of this polymorphism in UGT1A1 is associated with an increase in the incidence of hyperbilirubinemia when treated with pazopanib.Details
HLA class I histocompatibility antigen protein P5HLA-B*57:01(G;G)G alleleADR Directly StudiedThe presence of this polymorphism in HCP5 may indicate an increased risk of ALT elevation leading to drug-related hepatotoxicty from pazpanib therapy.Details

Interactions

Drug Interactions
DrugInteractionDrug group
AbemaciclibThe serum concentration of Pazopanib can be increased when it is combined with Abemaciclib.Approved, Investigational
AbirateroneThe serum concentration of Pazopanib can be increased when it is combined with Abiraterone.Approved
AcetaminophenThe serum concentration of Pazopanib can be increased when it is combined with Acetaminophen.Approved
Acetyl sulfisoxazoleThe metabolism of Pazopanib can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Pazopanib.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Pazopanib.Experimental
AfatinibThe serum concentration of Pazopanib can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Pazopanib can be increased when it is combined with Albendazole.Approved, Vet Approved
AlectinibThe serum concentration of Pazopanib can be increased when it is combined with Alectinib.Approved, Investigational
AlfentanilThe serum concentration of Pazopanib can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
AlmasilateThe serum concentration of Pazopanib can be decreased when it is combined with Almasilate.Approved, Experimental
AloglutamolThe serum concentration of Pazopanib can be decreased when it is combined with Aloglutamol.Approved
AluminiumThe serum concentration of Pazopanib can be decreased when it is combined with Aluminium.Approved, Investigational
Aluminium acetoacetateThe serum concentration of Pazopanib can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Pazopanib can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AmantadineThe serum concentration of Pazopanib can be increased when it is combined with Amantadine.Approved
Aminohippuric acidThe serum concentration of Pazopanib can be increased when it is combined with Aminohippuric acid.Approved, Investigational
AmiodaroneThe serum concentration of Pazopanib can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Pazopanib can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Pazopanib can be increased when it is combined with Amlodipine.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Pazopanib.Approved
AmprenavirThe serum concentration of Pazopanib can be increased when it is combined with Amprenavir.Approved, Investigational
AmsacrineThe serum concentration of Pazopanib can be increased when it is combined with Amsacrine.Approved, Investigational
AnagrelidePazopanib may increase the QTc-prolonging activities of Anagrelide.Approved
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Pazopanib.Approved, Investigational, Withdrawn
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Pazopanib is combined with Anthrax immune globulin human.Approved
ApalutamideThe serum concentration of Pazopanib can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineApomorphine may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
AprepitantThe serum concentration of Pazopanib can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
Arsenic trioxidePazopanib may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherPazopanib may increase the QTc-prolonging activities of Artemether.Approved
AsenapineAsenapine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AstemizoleThe serum concentration of Pazopanib can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Pazopanib.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Pazopanib can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Pazopanib can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Pazopanib can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Pazopanib is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Pazopanib can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Pazopanib can be increased when it is combined with Azithromycin.Approved
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Pazopanib is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Pazopanib is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BaricitinibThe serum concentration of Pazopanib can be increased when it is combined with Baricitinib.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Pazopanib.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Pazopanib is combined with Beclomethasone dipropionate.Approved, Investigational
BedaquilinePazopanib may increase the QTc-prolonging activities of Bedaquiline.Approved
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Pazopanib.Approved
Benzyl alcoholThe serum concentration of Pazopanib can be increased when it is combined with Benzyl alcohol.Approved
BepridilThe serum concentration of Pazopanib can be increased when it is combined with Bepridil.Approved, Withdrawn
BetaxololThe metabolism of Pazopanib can be decreased when combined with Betaxolol.Approved, Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Pazopanib.Approved, Investigational
BiperidenThe serum concentration of Pazopanib can be increased when it is combined with Biperiden.Approved, Investigational
Bismuth subcitrate potassiumThe serum concentration of Pazopanib can be decreased when it is combined with Bismuth Subcitrate.Approved, Investigational
Bismuth subnitrateThe serum concentration of Pazopanib can be decreased when it is combined with Bismuth subnitrate.Approved
BoceprevirThe serum concentration of Pazopanib can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Pazopanib can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Pazopanib can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Pazopanib can be increased when it is combined with Bosutinib.Approved
BrigatinibThe serum concentration of Pazopanib can be increased when it is combined with Brigatinib.Approved, Investigational
BromocriptineThe serum concentration of Pazopanib can be increased when it is combined with Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Pazopanib.Approved
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Pazopanib.Approved
BuprenorphineThe serum concentration of Pazopanib can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
BuspironeThe serum concentration of Pazopanib can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Pazopanib can be increased when it is combined with Cabazitaxel.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Pazopanib.Approved
CaffeineThe serum concentration of Pazopanib can be increased when it is combined with Caffeine.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium silicateThe serum concentration of Pazopanib can be decreased when it is combined with Calcium silicate.Experimental
CanagliflozinThe serum concentration of Pazopanib can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Pazopanib can be increased when it is combined with Candesartan.Experimental
Candesartan cilexetilThe serum concentration of Pazopanib can be increased when it is combined with Candesartan cilexetil.Approved
CannabidiolThe serum concentration of Pazopanib can be increased when it is combined with Cannabidiol.Approved, Investigational
CaptoprilThe serum concentration of Pazopanib can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Pazopanib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarvedilolThe serum concentration of Pazopanib can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Pazopanib can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Pazopanib can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Pazopanib can be increased when it is combined with Ceritinib.Approved
CerivastatinCerivastatin may increase the hepatotoxic activities of Pazopanib.Approved, Withdrawn
CetirizineThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Pazopanib.Approved
ChloroquineThe serum concentration of Pazopanib can be increased when it is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Pazopanib is combined with Chlorphenamine.Approved
ChlorpromazineThe serum concentration of Pazopanib can be increased when it is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideThe serum concentration of Pazopanib can be increased when it is combined with Chlorpropamide.Approved, Investigational
ChlorprothixeneThe serum concentration of Pazopanib can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
CholecalciferolThe metabolism of Pazopanib can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Pazopanib can be increased when it is combined with Cholesterol.Approved, Investigational
CilazaprilThe serum concentration of Pazopanib can be increased when it is combined with Cilazapril.Approved
CimetidineCimetidine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CinacalcetThe metabolism of Pazopanib can be decreased when combined with Cinacalcet.Approved
CinnarizineThe risk or severity of QTc prolongation can be increased when Pazopanib is combined with Cinnarizine.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Pazopanib.Approved, Investigational
CisapridePazopanib may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Pazopanib can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Pazopanib can be increased when it is combined with Clarithromycin.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Pazopanib is combined with Clemastine.Approved, Investigational
ClobazamThe metabolism of Pazopanib can be decreased when combined with Clobazam.Approved, Illicit
ClofazimineThe serum concentration of Pazopanib can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Pazopanib can be increased when it is combined with Clomipramine.Approved, Investigational, Vet Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Pazopanib is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClotrimazoleThe serum concentration of Pazopanib can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Pazopanib.Approved
CobicistatThe serum concentration of Pazopanib can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Pazopanib can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Pazopanib can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Pazopanib can be increased when it is combined with Colforsin.Experimental, Investigational
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Pazopanib.Approved, Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Pazopanib is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CrisaboroleThe metabolism of Pazopanib can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe serum concentration of Pazopanib can be increased when it is combined with Crizotinib.Approved
CurcuminThe serum concentration of Pazopanib can be increased when it is combined with Curcumin.Approved, Investigational
CyclophosphamideThe serum concentration of Pazopanib can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Pazopanib can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Pazopanib.Experimental
Cyproterone acetateThe serum concentration of Pazopanib can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Pazopanib can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe serum concentration of Pazopanib can be increased when it is combined with Daclatasvir.Approved, Investigational
DactinomycinThe serum concentration of Pazopanib can be increased when it is combined with Dactinomycin.Approved, Investigational
DaidzinThe serum concentration of Pazopanib can be increased when it is combined with Daidzin.Experimental
DarifenacinThe metabolism of Pazopanib can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Pazopanib can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Pazopanib can be increased when it is combined with Dasabuvir.Approved
DasatinibThe serum concentration of Pazopanib can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Pazopanib can be increased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Pazopanib can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Pazopanib.Approved
DelavirdineThe metabolism of Pazopanib can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Pazopanib.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Pazopanib.Approved
DesipramineThe serum concentration of Pazopanib can be increased when it is combined with Desipramine.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Pazopanib.Approved
DesloratadineThe serum concentration of Pazopanib can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Pazopanib can be increased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Pazopanib.Approved
DexlansoprazoleThe serum concentration of Pazopanib can be decreased when it is combined with Dexlansoprazole.Approved, Investigational
DexniguldipineThe serum concentration of Pazopanib can be increased when it is combined with Dexniguldipine.Experimental
DexrabeprazoleThe serum concentration of Pazopanib can be decreased when it is combined with Dexrabeprazole.Experimental
DexverapamilThe serum concentration of Pazopanib can be increased when it is combined with Dexverapamil.Experimental
DiethylstilbestrolThe serum concentration of Pazopanib can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DigitoxinDigitoxin may decrease the cardiotoxic activities of Pazopanib.Approved, Investigational
DigoxinThe serum concentration of Pazopanib can be increased when it is combined with Digoxin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pazopanib.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Pazopanib.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Pazopanib.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Pazopanib.Experimental
DihydroergotamineThe serum concentration of Pazopanib can be increased when it is combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe serum concentration of Pazopanib can be increased when it is combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Pazopanib is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Pazopanib.Approved, Investigational
DipyridamoleThe serum concentration of Pazopanib can be increased when it is combined with Dipyridamole.Approved
DisopyramidePazopanib may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pazopanib.Approved, Investigational
DofetilidePazopanib may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
DolasetronDolasetron may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
DomperidonePazopanib may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DosulepinThe metabolism of Pazopanib can be decreased when combined with Dosulepin.Approved
DoxazosinThe serum concentration of Pazopanib can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Pazopanib can be increased when it is combined with Doxepin.Approved, Investigational
DoxorubicinThe serum concentration of Pazopanib can be increased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Pazopanib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineThe risk or severity of QTc prolongation can be increased when Doxylamine is combined with Pazopanib.Approved, Vet Approved
DronabinolThe serum concentration of Pazopanib can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Pazopanib can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Pazopanib.Approved, Vet Approved
DuloxetineThe metabolism of Pazopanib can be decreased when combined with Duloxetine.Approved
EfavirenzThe metabolism of Pazopanib can be decreased when combined with Efavirenz.Approved, Investigational
ElacridarThe serum concentration of Pazopanib can be increased when it is combined with Elacridar.Investigational
EliglustatPazopanib may increase the QTc-prolonging activities of Eliglustat.Approved
EltrombopagThe serum concentration of Pazopanib can be increased when it is combined with Eltrombopag.Approved
EmopamilThe serum concentration of Pazopanib can be increased when it is combined with Emopamil.Experimental
EnalaprilThe serum concentration of Pazopanib can be increased when it is combined with Enalapril.Approved, Vet Approved
EnasidenibThe serum concentration of Pazopanib can be increased when it is combined with Enasidenib.Approved, Investigational
EnzalutamideThe serum concentration of Pazopanib can be increased when it is combined with Enzalutamide.Approved
EpinastineEpinastine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ErgonovineThe serum concentration of Pazopanib can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Pazopanib can be increased when it is combined with Ergotamine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
ErlotinibThe serum concentration of Pazopanib can be increased when it is combined with Erlotinib.Approved, Investigational
ErythromycinThe serum concentration of Pazopanib can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramPazopanib may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsomeprazoleThe serum concentration of Pazopanib can be decreased when it is combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Pazopanib can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Pazopanib can be increased when it is combined with Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Pazopanib can be increased when it is combined with Estradiol benzoate.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Pazopanib can be increased when it is combined with Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Pazopanib can be increased when it is combined with Estradiol dienanthate.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Pazopanib can be increased when it is combined with Estradiol valerate.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Pazopanib can be increased when it is combined with Estramustine.Approved, Investigational
EstroneThe serum concentration of Pazopanib can be increased when it is combined with Estrone.Approved
EtoposideThe serum concentration of Pazopanib can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Pazopanib can be increased when it is combined with Etravirine.Approved
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Pazopanib.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
FamotidineFamotidine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Pazopanib.Approved
FelodipineThe serum concentration of Pazopanib can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Pazopanib can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pazopanib.Approved
FexofenadineThe serum concentration of Pazopanib can be increased when it is combined with Fexofenadine.Approved, Investigational
FidaxomicinThe serum concentration of Pazopanib can be increased when it is combined with Fidaxomicin.Approved
FingolimodPazopanib may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Pazopanib.Approved, Withdrawn
FluconazoleThe serum concentration of Pazopanib can be increased when it is combined with Fluconazole.Approved, Investigational
FluoxetineThe serum concentration of Pazopanib can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Pazopanib can be increased when it is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe serum concentration of Pazopanib can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Pazopanib can be increased when it is combined with Flurazepam.Approved, Illicit, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Pazopanib is combined with Fluticasone propionate.Approved
FluvastatinFluvastatin may increase the hepatotoxic activities of Pazopanib.Approved
FluvoxamineThe serum concentration of Pazopanib can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
FosamprenavirThe metabolism of Pazopanib can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Pazopanib can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Pazopanib.Approved
FosphenytoinThe serum concentration of Pazopanib can be decreased when it is combined with Fosphenytoin.Approved, Investigational
Fusidic AcidThe serum concentration of Pazopanib can be increased when it is combined with Fusidic Acid.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Pazopanib is combined with G17DT.Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
GalantamineGalantamine may increase the QTc-prolonging activities of Pazopanib.Approved
GallopamilThe serum concentration of Pazopanib can be increased when it is combined with Gallopamil.Investigational
GefitinibThe serum concentration of Pazopanib can be increased when it is combined with Gefitinib.Approved, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Pazopanib.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
GenisteinThe serum concentration of Pazopanib can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Pazopanib is combined with GI-5005.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Pazopanib.Experimental
GlecaprevirThe serum concentration of Pazopanib can be increased when it is combined with Glecaprevir.Approved, Investigational
GlyburideThe serum concentration of Pazopanib can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Pazopanib can be increased when it is combined with Glycerin.Approved, Investigational
GoserelinGoserelin may increase the QTc-prolonging activities of Pazopanib.Approved
Gramicidin DThe serum concentration of Pazopanib can be increased when it is combined with Gramicidin D.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
GrepafloxacinThe serum concentration of Pazopanib can be increased when it is combined with Grepafloxacin.Approved, Investigational, Withdrawn
HaloperidolThe serum concentration of Pazopanib can be increased when it is combined with Haloperidol.Approved
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Pazopanib is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Pazopanib is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HesperetinThe serum concentration of Pazopanib can be increased when it is combined with Hesperetin.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Pazopanib.Approved
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Pazopanib is combined with Human rabies virus immune globulin.Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Pazopanib.Approved, Illicit
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pazopanib.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of adverse effects can be increased when Pazopanib is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of adverse effects can be increased when Pazopanib is combined with Hydrocortisone butyrate.Approved, Vet Approved
HydrotalciteThe serum concentration of Pazopanib can be decreased when it is combined with Hydrotalcite.Approved, Experimental, Investigational
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Pazopanib.Approved
IbandronateThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pazopanib is combined with Ibandronate.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Pazopanib.Approved
IbuprofenThe serum concentration of Pazopanib can be increased when it is combined with Ibuprofen.Approved
IbutilidePazopanib may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Pazopanib can be increased when it is combined with Idelalisib.Approved
IloperidonePazopanib may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe serum concentration of Pazopanib can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Pazopanib can be increased when it is combined with Imipramine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Pazopanib.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Pazopanib.Approved
IndinavirThe serum concentration of Pazopanib can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Pazopanib can be increased when it is combined with Indomethacin.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Pazopanib is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Pazopanib is combined with INGN 225.Investigational
IrbesartanThe metabolism of Pazopanib can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Pazopanib.Approved, Investigational
IsavuconazoleThe serum concentration of Pazopanib can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Pazopanib can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsofluraneIsoflurane may increase the QTc-prolonging activities of Pazopanib.Approved, Vet Approved
IsoniazidThe metabolism of Pazopanib can be decreased when combined with Isoniazid.Approved, Investigational
IsradipineThe serum concentration of Pazopanib can be increased when it is combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Pazopanib can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Pazopanib.Approved
IvacaftorThe serum concentration of Pazopanib can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Pazopanib can be increased when it is combined with Ivermectin.Approved, Investigational, Vet Approved
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Pazopanib is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
KetamineThe serum concentration of Pazopanib can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Pazopanib can be increased when it is combined with Ketoconazole.Approved, Investigational
LafutidineLafutidine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Pazopanib.Experimental
LansoprazoleThe serum concentration of Pazopanib can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
LavoltidineLavoltidine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Pazopanib is combined with Leflunomide.Approved, Investigational
LenvatinibPazopanib may increase the QTc-prolonging activities of Lenvatinib.Approved, Investigational
LetermovirThe serum concentration of Pazopanib can be increased when it is combined with Letermovir.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
LevofloxacinThe serum concentration of Pazopanib can be increased when it is combined with Levofloxacin.Approved, Investigational
LidocaineThe serum concentration of Pazopanib can be increased when it is combined with Lidocaine.Approved, Vet Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Pazopanib.Approved, Investigational
Lithium cationLithium may increase the QTc-prolonging activities of Pazopanib.Experimental
LobeglitazoneThe metabolism of Pazopanib can be decreased when combined with Lobeglitazone.Approved, Investigational
LomerizineThe serum concentration of Pazopanib can be increased when it is combined with Lomerizine.Experimental
LomitapideThe serum concentration of Pazopanib can be increased when it is combined with Lomitapide.Approved, Investigational
LoperamideThe serum concentration of Pazopanib can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Pazopanib can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Pazopanib can be increased when it is combined with Loratadine.Approved, Investigational
LorcaserinThe metabolism of Pazopanib can be decreased when combined with Lorcaserin.Approved
LorpiprazoleThe serum concentration of Pazopanib can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Pazopanib can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Pazopanib can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Pazopanib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Pazopanib can be increased when it is combined with Lumacaftor.Approved
LumefantrinePazopanib may increase the QTc-prolonging activities of Lumefantrine.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Pazopanib.Illicit, Investigational, Withdrawn
MagaldrateThe serum concentration of Pazopanib can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideThe serum concentration of Pazopanib can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Pazopanib can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Pazopanib can be decreased when it is combined with Magnesium silicate.Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MaprotilineThe serum concentration of Pazopanib can be increased when it is combined with Maprotiline.Approved, Investigational
MebendazoleThe serum concentration of Pazopanib can be increased when it is combined with Mebendazole.Approved, Vet Approved
Medical CannabisThe serum concentration of Pazopanib can be increased when it is combined with Medical Cannabis.Experimental, Investigational
MefloquineThe serum concentration of Pazopanib can be increased when it is combined with Mefloquine.Approved, Investigational
Megestrol acetateThe serum concentration of Pazopanib can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MeprobamateThe serum concentration of Pazopanib can be increased when it is combined with Meprobamate.Approved, Illicit
MepyramineThe risk or severity of QTc prolongation can be increased when Mepyramine is combined with Pazopanib.Approved, Vet Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Pazopanib.Experimental
MethadoneThe serum concentration of Pazopanib can be increased when it is combined with Methadone.Approved
MethanthelineMethantheline can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethimazoleThe risk or severity of adverse effects can be increased when Pazopanib is combined with Methimazole.Approved
MethotrimeprazineThe metabolism of Pazopanib can be decreased when combined with Methotrimeprazine.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Pazopanib.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pazopanib.Approved, Vet Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Pazopanib.Approved
MetiamideMetiamide can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Pazopanib.Experimental
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Pazopanib.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Pazopanib.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Pazopanib.Approved
MevastatinMevastatin may increase the hepatotoxic activities of Pazopanib.Experimental
MexiletineThe metabolism of Pazopanib can be decreased when combined with Mexiletine.Approved, Investigational
MibefradilThe serum concentration of Pazopanib can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Pazopanib can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Pazopanib can be increased when it is combined with Midazolam.Approved, Illicit
MidostaurinThe metabolism of Pazopanib can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Pazopanib can be increased when it is combined with Mifepristone.Approved, Investigational
MifepristoneMifepristone may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
MirabegronThe metabolism of Pazopanib can be decreased when combined with Mirabegron.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Pazopanib.Approved
MitomycinThe serum concentration of Pazopanib can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Pazopanib can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Pazopanib can be increased when it is combined with Mitoxantrone.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Pazopanib.Approved
MorphineThe serum concentration of Pazopanib can be increased when it is combined with Morphine.Approved, Investigational
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Pazopanib.Approved, Investigational
NabiloneThe metabolism of Pazopanib can be decreased when combined with Nabilone.Approved, Investigational
NabiximolsThe serum concentration of Pazopanib can be increased when it is combined with Nabiximols.Approved, Investigational
NaltrexoneThe serum concentration of Pazopanib can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Pazopanib can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Pazopanib is combined with Natalizumab.Approved, Investigational
NefazodoneThe serum concentration of Pazopanib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Pazopanib can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Pazopanib can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Pazopanib can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Pazopanib can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Pazopanib can be increased when it is combined with Nicardipine.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Pazopanib.Approved, Investigational
NiguldipineThe serum concentration of Pazopanib can be increased when it is combined with Niguldipine.Experimental
NilotinibThe serum concentration of Pazopanib can be increased when it is combined with Nilotinib.Approved, Investigational
NimodipineThe serum concentration of Pazopanib can be increased when it is combined with Nimodipine.Approved, Investigational
NiperotidineNiperotidine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
NisoldipineThe serum concentration of Pazopanib can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Pazopanib can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Pazopanib can be increased when it is combined with Nitrendipine.Approved, Investigational
NizatidineNizatidine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Pazopanib.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Pazopanib.Approved
NovobiocinThe serum concentration of Pazopanib can be increased when it is combined with Novobiocin.Approved, Investigational, Vet Approved
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Pazopanib.Approved, Investigational
OctreotideOctreotide may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Pazopanib.Approved
OlanzapineOlanzapine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
OlaparibThe metabolism of Pazopanib can be decreased when combined with Olaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Pazopanib.Experimental, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Pazopanib.Approved
OmeprazoleThe serum concentration of Pazopanib can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Ondansetron is combined with Pazopanib.Approved
OsimertinibThe serum concentration of Pazopanib can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Pazopanib.Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Pazopanib.Approved, Vet Approved
P-NitrophenolThe serum concentration of Pazopanib can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Pazopanib can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Pazopanib can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidonePazopanib may increase the QTc-prolonging activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Pazopanib can be increased when it is combined with Palmitic Acid.Approved, Experimental
PanobinostatThe serum concentration of Pazopanib can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Pazopanib can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Pazopanib can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Pazopanib can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
PentobarbitalThe serum concentration of Pazopanib can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Pazopanib.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Pazopanib.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Pazopanib can be increased when it is combined with Perindopril.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Pazopanib.Experimental
PheniramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Pazopanib.Approved
PhenobarbitalThe serum concentration of Pazopanib can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenytoinThe serum concentration of Pazopanib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Pazopanib can be increased when it is combined with Pibrentasvir.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pazopanib.Approved, Investigational
PimozideThe serum concentration of Pazopanib can be increased when it is combined with Pimozide.Approved
PioglitazoneThe metabolism of Pazopanib can be decreased when combined with Pioglitazone.Approved, Investigational
PitavastatinPitavastatin may increase the hepatotoxic activities of Pazopanib.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Pazopanib.Approved, Investigational
PonatinibThe serum concentration of Pazopanib can be increased when it is combined with Ponatinib.Approved, Investigational
PosaconazoleThe serum concentration of Pazopanib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pazopanib can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Pazopanib can be increased when it is combined with Prazosin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Pazopanib.Approved, Vet Approved
PrednisoneThe serum concentration of Pazopanib can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Pazopanib.Approved
PrimidoneThe serum concentration of Pazopanib can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Pazopanib can be increased when it is combined with Probenecid.Approved, Investigational
ProcainamidePazopanib may increase the QTc-prolonging activities of Procainamide.Approved
ProgesteroneThe serum concentration of Pazopanib can be increased when it is combined with Progesterone.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Pazopanib.Approved, Vet Approved
PromethazineThe serum concentration of Pazopanib can be increased when it is combined with Promethazine.Approved, Investigational
PropafenoneThe serum concentration of Pazopanib can be increased when it is combined with Propafenone.Approved
PropofolPropofol may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational, Vet Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Pazopanib.Experimental
ProtriptylineThe serum concentration of Pazopanib can be increased when it is combined with Protriptyline.Approved
QuercetinThe serum concentration of Pazopanib can be increased when it is combined with Quercetin.Experimental, Investigational
QuetiapineThe risk or severity of QTc prolongation can be increased when Pazopanib is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Pazopanib can be increased when it is combined with Quinacrine.Approved, Investigational
QuinidineThe serum concentration of Pazopanib can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe serum concentration of Pazopanib can be increased when it is combined with Quinine.Approved
RabeprazoleThe serum concentration of Pazopanib can be decreased when it is combined with Rabeprazole.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Pazopanib is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pazopanib.Approved, Investigational
RanitidineThe serum concentration of Pazopanib can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Pazopanib can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Pazopanib can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Pazopanib can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Pazopanib can be increased when it is combined with Reserpine.Approved, Investigational
RifabutinThe serum concentration of Pazopanib can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Pazopanib can be increased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Pazopanib can be decreased when it is combined with Rifapentine.Approved, Investigational
RilpivirineThe serum concentration of Pazopanib can be increased when it is combined with Rilpivirine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Pazopanib is combined with Rindopepimut.Investigational
RisperidoneRisperidone may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
RitonavirThe serum concentration of Pazopanib can be increased when it is combined with Ritonavir.Approved, Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Pazopanib.Approved
RolapitantThe serum concentration of Pazopanib can be increased when it is combined with Rolapitant.Approved, Investigational
RopiniroleThe metabolism of Pazopanib can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe metabolism of Pazopanib can be decreased when combined with Rosiglitazone.Approved, Investigational
RosuvastatinRosuvastatin may increase the hepatotoxic activities of Pazopanib.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Pazopanib is combined with Rotavirus Vaccine.Approved
Roxatidine acetateRoxatidine acetate can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Pazopanib is combined with Rubella virus vaccine.Approved, Investigational
RucaparibThe serum concentration of Pazopanib can be increased when it is combined with Rucaparib.Approved, Investigational
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Pazopanib.Approved, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Pazopanib.Approved
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Pazopanib is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
SaquinavirThe serum concentration of Pazopanib can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Pazopanib can be decreased when used in combination with Sarilumab.Approved, Investigational
SecobarbitalThe metabolism of Pazopanib can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Pazopanib can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Pazopanib can be increased when it is combined with Sertraline.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Pazopanib.Approved, Vet Approved
SildenafilThe metabolism of Pazopanib can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Pazopanib can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Pazopanib can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Pazopanib can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Pazopanib can be increased when it is combined with Sirolimus.Approved, Investigational
Sodium bicarbonateThe serum concentration of Pazopanib can be decreased when it is combined with Sodium bicarbonate.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Pazopanib.Approved
SorafenibThe serum concentration of Pazopanib can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolPazopanib may increase the QTc-prolonging activities of Sotalol.Approved
SRP 299The risk or severity of adverse effects can be increased when Pazopanib is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Pazopanib can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StaurosporineThe serum concentration of Pazopanib can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Pazopanib can be increased when it is combined with Stiripentol.Approved
SulfamethoxazoleThe metabolism of Pazopanib can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe serum concentration of Pazopanib can be increased when it is combined with Sulfasalazine.Approved
SulfinpyrazoneThe serum concentration of Pazopanib can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Pazopanib.Approved, Vet Approved
SunitinibThe serum concentration of Pazopanib can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Pazopanib can be increased when it is combined with Tacrine.Investigational, Withdrawn
TacrolimusThe serum concentration of Pazopanib can be increased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Pazopanib can be increased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Pazopanib can be increased when it is combined with Taurocholic Acid.Experimental
TecemotideThe risk or severity of adverse effects can be increased when Pazopanib is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Pazopanib can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Pazopanib.Approved
TelithromycinThe serum concentration of Pazopanib can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Pazopanib can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Pazopanib can be increased when it is combined with Temsirolimus.Approved
Tenofovir disoproxilThe metabolism of Pazopanib can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinThe serum concentration of Pazopanib can be increased when it is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Pazopanib.Approved
TerfenadineThe serum concentration of Pazopanib can be increased when it is combined with Terfenadine.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Pazopanib.Experimental
TeriflunomideThe serum concentration of Pazopanib can be decreased when it is combined with Teriflunomide.Approved
TerodilineThe risk or severity of QTc prolongation can be increased when Pazopanib is combined with Terodiline.Experimental
TestosteroneThe serum concentration of Pazopanib can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Pazopanib can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Pazopanib can be increased when it is combined with Testosterone enanthate.Approved
Testosterone undecanoateThe serum concentration of Pazopanib can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TetrabenazinePazopanib may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
TetrandrineThe serum concentration of Pazopanib can be increased when it is combined with Tetrandrine.Experimental
TG4010The risk or severity of adverse effects can be increased when Pazopanib is combined with TG4010.Investigational
TheophyllineThe metabolism of Pazopanib can be decreased when combined with Theophylline.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Pazopanib.Approved, Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Pazopanib.Approved
TicagrelorThe serum concentration of Pazopanib can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Pazopanib can be decreased when combined with Ticlopidine.Approved
TipranavirThe metabolism of Pazopanib can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
TocilizumabThe serum concentration of Pazopanib can be decreased when it is combined with Tocilizumab.Approved
TofacitinibPazopanib may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolterodineTolterodine may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
TolvaptanThe serum concentration of Pazopanib can be increased when it is combined with Tolvaptan.Approved
TopiroxostatThe serum concentration of Pazopanib can be increased when it is combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Pazopanib can be increased when it is combined with Topotecan.Approved, Investigational
ToremifenePazopanib may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TranylcypromineThe metabolism of Pazopanib can be decreased when combined with Tranylcypromine.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Pazopanib.Approved, Investigational
TrazodoneTrazodone may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
TrifluoperazineThe serum concentration of Pazopanib can be increased when it is combined with Trifluoperazine.Approved, Investigational
TriflupromazineThe serum concentration of Pazopanib can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Pazopanib can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Pazopanib can be increased when it is combined with Trimipramine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Pazopanib.Approved, Vet Approved
TroleandomycinThe serum concentration of Pazopanib can be increased when it is combined with Troleandomycin.Approved
TromethamineThe serum concentration of Pazopanib can be decreased when it is combined with Tromethamine.Approved
Typhoid VaccineThe risk or severity of adverse effects can be increased when Pazopanib is combined with Typhoid Vaccine.Approved
Valproic AcidThe risk or severity of QTc prolongation can be increased when Pazopanib is combined with Valproic Acid.Approved, Investigational
VandetanibThe serum concentration of Pazopanib can be increased when it is combined with Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Pazopanib.Approved
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Pazopanib is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VelpatasvirThe serum concentration of Pazopanib can be increased when it is combined with Velpatasvir.Approved, Investigational
VemurafenibThe serum concentration of Pazopanib can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Pazopanib can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Pazopanib can be increased when it is combined with Verapamil.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Pazopanib.Approved
VinblastineThe serum concentration of Pazopanib can be increased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Pazopanib can be increased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Pazopanib can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Pazopanib can be increased when it is combined with Vismodegib.Approved, Investigational
VoacamineThe serum concentration of Pazopanib can be increased when it is combined with Voacamine.Approved, Investigational
VoriconazoleThe serum concentration of Pazopanib can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
VoxilaprevirThe serum concentration of Pazopanib can be increased when it is combined with Voxilaprevir.Approved, Investigational
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Pazopanib is combined with Yellow Fever Vaccine.Approved, Investigational
ZidovudineThe risk or severity of adverse effects can be increased when Pazopanib is combined with Zidovudine.Approved
ZimelidineThe serum concentration of Pazopanib can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidonePazopanib may increase the QTc-prolonging activities of Ziprasidone.Approved
Zoledronic acidThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pazopanib is combined with Zoledronic acid.Approved
ZucapsaicinThe metabolism of Pazopanib can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolPazopanib may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid drinking grapefruit juice as it is a CYP 3A4 inhibitor and will increase exposure of pazopanib
  • Bioavailability increases with food. Take pazopanib on empty stomach.

References

General References
  1. Sonpavde G, Hutson TE, Sternberg CN: Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin Investig Drugs. 2008 Feb;17(2):253-61. doi: 10.1517/13543784.17.2.253. [PubMed:18230058]
  2. Verweij J, Sleijfer S: Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35. doi: 10.1517/14656566.2013.780030. Epub 2013 Mar 14. [PubMed:23488774]
  3. Deng Y, Sychterz C, Suttle AB, Dar MM, Bershas D, Negash K, Qian Y, Chen EP, Gorycki PD, Ho MY: Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013 May;43(5):443-53. doi: 10.3109/00498254.2012.734642. Epub 2012 Nov 16. [PubMed:23548165]
  4. Deeks ED: Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000. [PubMed:23072642]
External Links
KEGG Drug
D05380
PubChem Compound
10113978
PubChem Substance
175427074
ChemSpider
8289501
BindingDB
26474
ChEBI
71219
ChEMBL
CHEMBL477772
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Pazopanib
ATC Codes
L01XE11 — Pazopanib
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (593 KB)
MSDS
Download (70.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentRenal Cell Adenocarcinoma1
0CompletedTreatmentRenal Cell Adenocarcinoma1
1Active Not RecruitingOtherCholangiocarcinomas / Soft-Tissue Sarcoma / Thyroid Cancers / Tumors, Solid1
1Active Not RecruitingTreatmentAdvanced Cancers1
1Active Not RecruitingTreatmentAdvanced Cancers / Tumors, Solid1
1Active Not RecruitingTreatmentBreast Cancer - Female / Unspecified Adult Solid Tumor - Protocol Specific1
1Active Not RecruitingTreatmentCancer of the Ovary / Cancer, Breast / Carcinoma, Colorectal / Carcinoma, Pancreatic / Melanoma / Non-Small Cell Lung Carcinoma (NSCLC) / Prostate Cancer / Renal Cell Adenocarcinoma / Tumors, Solid1
1Active Not RecruitingTreatmentClear-cell Metastatic Renal Cell Carcinoma / Renal Cell Adenocarcinoma1
1Active Not RecruitingTreatmentMetastatic Disease / Renal Cell Adenocarcinoma / Soft Tissue Sarcoma (STS)1
1Active Not RecruitingTreatmentMetastatic Renal Cell Carcinoma1
1Active Not RecruitingTreatmentMetastatic Solid Tumors1
1Active Not RecruitingTreatmentSolid Neoplasms1
1Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1Active Not RecruitingTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1CompletedOtherTumors, Solid1
1CompletedScreeningTumors, Solid1
1CompletedSupportive CareAge Related Macular Degeneration (ARMD) / Macular Degeneration1
1CompletedTreatmentAdvanced Cancers1
1CompletedTreatmentAdvanced Solid Tumours / Cancers / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedTreatmentCancer, Advanced1
1CompletedTreatmentCancers / Renal Cell Adenocarcinoma3
1CompletedTreatmentCarcinoma, Hepatic Cell / Hepatocellular,Carcinoma / Liver Cancer1
1CompletedTreatmentCentral nervous system neoplasms malignant NEC / Genitourinary Neoplasms Malignancy and Gender Unspecified / Malignant Neoplasm of Breast / Malignant Neoplasm of Gastrointestinal Tract / Malignant Neoplasm of Thorax / Melanoma / Neoplasms, Head and Neck1
1CompletedTreatmentChildhood Central Nervous System Choriocarcinoma / Childhood Central Nervous System Embryonal Tumor / Childhood Central Nervous System Germ Cell Tumor / Childhood Central Nervous System Germinoma / Childhood Central Nervous System Mixed Germ Cell Tumor / Childhood Central Nervous System Teratoma / Childhood Central Nervous System Yolk Sac Tumor / Metastatic Childhood Soft Tissue Sarcoma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Central Nervous System Embryonal Tumor / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Childhood Visual Pathway Glioma / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentColorectal Cancers / Neoplasms, Colorectal2
1CompletedTreatmentGynecologic Tumors1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
1CompletedTreatmentMacular Degeneration2
1CompletedTreatmentMalignant Lymphomas / Neoplasms1
1CompletedTreatmentMetastatic Cancers / Tumors, Solid1
1CompletedTreatmentNeoplasms, Breast1
1CompletedTreatmentNeoplasms, Breast / Solid Tumor Cancers1
1CompletedTreatmentNeoplasms, Ovarian1
1CompletedTreatmentNeoplasms / Sarcomas / Stomach Neoplasms1
1CompletedTreatmentProstate Cancer1
1CompletedTreatmentPsoriasis / Psoriasis Vulgaris (Plaque Psoriasis)1
1CompletedTreatmentRecurrent Thyroid Cancer / Stage IVA Follicular Thyroid Cancer / Stage IVA Papillary Thyroid Cancer / Stage IVB Follicular Thyroid Cancer / Stage IVB Papillary Thyroid Cancer / Stage IVC Follicular Thyroid Cancer / Stage IVC Papillary Thyroid Cancer1
1CompletedTreatmentRenal Cancers / Tumors, Solid1
1CompletedTreatmentRenal Cell Adenocarcinoma2
1CompletedTreatmentRenal Cell Adenocarcinoma / Solid Tumor Cancers1
1CompletedTreatmentRenal Cell Adenocarcinoma / Tumors, Solid1
1CompletedTreatmentSoft Tissue Sarcoma (STS)1
1CompletedTreatmentTumors, Solid1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1RecruitingOtherCancers1
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small Cell Lung Carcinoma (NSCLC)1
1RecruitingTreatmentSarcomas1
1TerminatedTreatmentCancer, Breast / Head and Neck Carcinoma / Hepatocellular Cancer / Lung Cancers / Malignant Neoplasm of Colon / Malignant Neoplasm of Pancreas / Renal Cancers / Sarcomas1
1TerminatedTreatmentMale Breast Carcinoma / Recurrent Breast Carcinoma / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer1
1TerminatedTreatmentMetastatic Breast Cancer (MBC) / Metastatic Non Small Cell Lung Cancer1
1TerminatedTreatmentMetastatic Cancer (Different Solid Tumour Types)1
1TerminatedTreatmentMetastatic Cancers1
1WithdrawnTreatmentAnaplastic Gliomas / Gliosarcoma / Recurrent Glioblastoma1
1WithdrawnTreatmentNeoplasms, Brain / Neuroblastomas / Sarcoma, Osteogenic / Sarcomas / Wilms' tumor1
1WithdrawnTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2Active Not RecruitingTreatmentAdvanced Renal Cell Carcinoma1
1, 2Active Not RecruitingTreatmentAdvanced Soft Tissue Sarcoma1
1, 2Active Not RecruitingTreatmentRenal Cell Adenocarcinoma1
1, 2CompletedTreatmentAdvanced Urothelial Cancer of Bladder After Failure of Platinum-containing Therapy1
1, 2CompletedTreatmentCorneal Neovascularization1
1, 2CompletedTreatmentOperable Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma1
1, 2CompletedTreatmentOvarian Epithelial Cancer1
1, 2Enrolling by InvitationTreatmentTumors, Solid1
1, 2RecruitingTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
1, 2RecruitingTreatmentCancer of the Ovary / Neoplasms, Ovarian1
1, 2RecruitingTreatmentClear Cell Renal Cell Carcinoma / Stage IV Renal Cell Cancer1
1, 2RecruitingTreatmentGlioblastoma Multiforme (GBM)1
1, 2RecruitingTreatmentHigh Grade Sarcoma / Metastatic Leiomyosarcoma / Metastatic Malignant Peripheral Nerve Sheath Tumor / Metastatic Synovial Sarcoma / Metastatic Undifferentiated Pleomorphic Sarcoma / Myxofibrosarcoma / Recurrent Leiomyosarcoma / Recurrent Malignant Peripheral Nerve Sheath Tumor / Recurrent Synovial Sarcoma / Recurrent Undifferentiated Pleomorphic Sarcoma / Uterine Corpus Leiomyosarcoma1
1, 2RecruitingTreatmentPancreatic Alpha Cell Carcinoma / Pancreatic Beta Islet Cell Carcinoma / Pancreatic Delta Cell Carcinoma / Pancreatic G-cell Carcinoma / Recurrent Islet Cell Carcinoma1
1, 2RecruitingTreatmentTumors, Central Nervous System / Tumors, Solid1
1, 2TerminatedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cancer1
1, 2TerminatedTreatmentMalignant Neoplasm of Stomach1
2Active Not RecruitingTreatmentAdenocarcinoma of the Prostate1
2Active Not RecruitingTreatmentAtypical Carcinoid Tumor / Foregut Carcinoid Tumor / Hindgut Carcinoid Tumor / Lung Carcinoid Tumor / Metastatic Carcinoid Tumors / Metastatic Digestive System Neuroendocrine Tumor G1 / Midgut Carcinoid Tumor / Recurrent Digestive System Neuroendocrine Tumor G1 / Regional Digestive System Neuroendocrine Tumor G11
2Active Not RecruitingTreatmentCancer of the Ovary / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm1
2Active Not RecruitingTreatmentCancer, Breast / Neoplasms, Breast1
2Active Not RecruitingTreatmentCarcinoma of the Collecting Ducts of Bellini / Chromophobe Renal Cell Carcinoma / Kidney Medullary Carcinoma / Kidney Oncocytoma / Metastatic Renal Cell Cancer / Papillary Renal Cell Carcinoma / Renal Cell Carcinoma Recurrent / Sarcomatoid Renal Cell Carcinoma / Stage IV Renal Cell Cancer / Type 1 Papillary Renal Cell Carcinoma / Type 2 Papillary Renal Cell Carcinoma1
2Active Not RecruitingTreatmentCentral Nervous System Neoplasms / Glioblastoma Multiforme (GBM) / Glioblastomas / Gliosarcoma / Neoplasms, Brain1
2Active Not RecruitingTreatmentClear Cell Renal Cell Carcinoma / Renal Cell Cancer, Recurrent / Stage IV Renal Cell Cancer1
2Active Not RecruitingTreatmentHormone-Resistant Prostate Cancer / Recurrent Prostate Carcinoma1
2Active Not RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2Active Not RecruitingTreatmentRecurrent Thyroid Gland Carcinoma / Stage III Differentiated Thyroid Gland Carcinoma / Stage III Differentiated Thyroid Gland Carcinoma AJCC v7 / Stage III Thyroid Gland Medullary Carcinoma / Stage III Thyroid Gland Medullary Carcinoma AJCC v7 / Stage IVA Differentiated Thyroid Gland Carcinoma / Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7 / Stage IVA Thyroid Gland Medullary Carcinoma / Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7 / Stage IVA Thyroid Gland Undifferentiated (Anaplastic) Carcinoma / Stage IVA Thyroid Gland Undifferentiated (Anaplastic) Carcinoma AJCC v7 / Stage IVB Differentiated Thyroid Gland Carcinoma / Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7 / Stage IVB Thyroid Gland Medullary Carcinoma / Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7 / Stage IVB Thyroid Gland Undifferentiated (Anaplastic) Carcinoma / Stage IVB Thyroid Gland Undifferentiated (Anaplastic) Carcinoma AJCC v7 / Stage IVC Differentiated Thyroid Gland Carcinoma / Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7 / Stage IVC Thyroid Gland Medullary Carcinoma / Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7 / Stage IVC Thyroid Gland Undifferentiated (Anaplastic) Carcinoma / Stage IVC Thyroid Gland Undifferentiated (Anaplastic) Carcinoma AJCC v7 / Thyroglobulin Antibody Negative / Thyroid Gland Undifferentiated (Anaplastic) Carcinoma1
2Active Not RecruitingTreatmentRenal Cancers2
2Active Not RecruitingTreatmentRenal Cell Adenocarcinoma2
2Active Not RecruitingTreatmentRenal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage III Renal Cell Cancer AJCC v7 / Stage IV Renal Cell Cancer / Stage IV Renal Cell Cancer AJCC V71
2Active Not RecruitingTreatmentSalivary Gland Carcinoma1
2Active Not RecruitingTreatmentSarcomas1
2Active Not RecruitingTreatmentSoft Tissue Sarcoma (STS)1
2Active Not RecruitingTreatmentStage III Melanoma / Stage IV Melanoma / Unresectable Melanoma1
2Active Not RecruitingTreatmentThyroid Gland Undifferentiated (Anaplastic) Carcinoma1
2Active Not RecruitingTreatmentVon Hippel-Lindau Syndrome1
2CompletedSupportive CareLymphedema of the extremities1
2CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
2CompletedTreatmentAdvanced Malignant Mesothelioma / Localized Malignant Mesothelioma / Recurrent Malignant Mesothelioma1
2CompletedTreatmentAdvanced and / or Metastatic Liposarcoma1
2CompletedTreatmentAdvanced/Metastatic Neuroendocrine Tumors1
2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
2CompletedTreatmentCancer of the Ovary1
2CompletedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Malignant Tumor of Peritoneum / Neoplasms, Ovarian1
2CompletedTreatmentCancer, Breast / Male Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentCancers / Cervix Diseases / Neoplasms, Ovarian / Ovarian Epithelial Cancer / Primary Peritoneal Carcinoma / Tumors / Uterine Diseases1
2CompletedTreatmentChondrosarcomas / Metastatic Chondrosarcoma1
2CompletedTreatmentClear Cell Renal Cell Carcinoma1
2CompletedTreatmentClear Cell Renal Cell Carcinoma / Stage I Renal Cell Cancer / Stage II Renal Cell Cancer / Stage III Renal Cell Cancer1
2CompletedTreatmentDistal Urethral Cancer / Metastatic Bladder Cancer / Proximal Urethral Cancer / Recurrent Bladder Cancer / Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Urethral Cancer / Transitional Cell Carcinoma of the Bladder / Urethral Cancer Associated With Invasive Bladder Cancer1
2CompletedTreatmentGIST1
2CompletedTreatmentGastrin-Producing Neuroendocrine Tumor / Lung Carcinoid Tumor / Metastatic Digestive System Neuroendocrine Tumor G1 / Multiple Endocrine Neoplasia Type 1 / Pancreatic Glucagonoma / Pancreatic Insulinoma / Pancreatic Polypeptide Tumor / Recurrent Digestive System Neuroendocrine Tumor G1 / Recurrent Pancreatic Neuroendocrine Carcinoma / Regional Digestive System Neuroendocrine Tumor G1 / Somatostatin-Producing Neuroendocrine Tumor1
2CompletedTreatmentGastrointestinal Stromal Tumors1
2CompletedTreatmentGliomas1
2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2CompletedTreatmentLiposarcoma / Metastatic Liposarcoma / Surgically Unresectable Liposarcoma1
2CompletedTreatmentLocally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
2CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC) / Lung Cancers1
2CompletedTreatmentLung Cancers1
2CompletedTreatmentMacular Degeneration2
2CompletedTreatmentMalignant Neoplasm of Stomach1
2CompletedTreatmentMultiple Myeloma (MM) / Renal Cell Adenocarcinoma1
2CompletedTreatmentNeoplasms, Breast3
2CompletedTreatmentNeoplasms, Ovarian1
2CompletedTreatmentNeoplasms, Uterine Cervix / Recurrent, IV-B Cervical cancer1
2CompletedTreatmentNeuroendocrine Tumors1
2CompletedTreatmentPlatinum-resistant Advanced Ovarian Cancer1
2CompletedTreatmentRecurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2CompletedTreatmentRecurrent Lymphoepithelioma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Stage IV Lymphoepithelioma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx1
2CompletedTreatmentRecurrent Melanoma / Stage IV Cutaneous Melanoma AJCC v6 and v7 / Stage IV Skin Melanoma1
2CompletedTreatmentRecurrent Prostate Cancer1
2CompletedTreatmentRecurrent Uterine Corpus Sarcoma / Uterine Carcinosarcoma1
2CompletedTreatmentRenal Cell Adenocarcinoma3
2CompletedTreatmentSoft Tissue Sarcoma (STS)1
2Not Yet RecruitingTreatmentSoft Tissue Sarcoma (STS)1
2RecruitingTreatmentAdult Alveolar Soft Part Sarcoma / Adult Angiosarcoma / Adult Desmoplastic Small Round Cell Tumor / Adult Epithelioid Hemangioendothelioma / Adult Epithelioid Sarcoma / Adult Extraskeletal Myxoid Chondrosarcoma / Adult Extraskeletal Osteosarcoma / Adult Fibrosarcoma / Adult Leiomyosarcoma / Adult Liposarcoma / Adult Malignant Mesenchymoma / Adult Malignant Peripheral Nerve Sheath Tumor / Adult Rhabdomyosarcoma / Adult Synovial Sarcoma / Adult Undifferentiated Pleomorphic Sarcoma / Malignant Adult Hemangiopericytoma / Recurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2RecruitingTreatmentAdult Angiosarcoma / Recurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2RecruitingTreatmentAdult Liposarcoma / Metastatic Bone Sarcomas / Metastatic Liposarcoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Liposarcoma / Recurrent Osteosarcoma / Stage IV Adult Soft Tissue Sarcoma1
2RecruitingTreatmentAdvanced Renal Cell Carcinoma / Metastatic Renal Cell Carcinoma1
2RecruitingTreatmentBiliary Carcinoma / Carcinoma of Gallbladder / Cholangiocarcinomas1
2RecruitingTreatmentCancer of the Ovary1
2RecruitingTreatmentClear Cell Metastatic Renal Cell Carcinoma1
2RecruitingTreatmentClear Cell Renal Cell Carcinoma / Stage III Renal Cell Cancer AJCC v8 / Stage IV Renal Cell Cancer / Stage IV Renal Cell Cancer AJCC V71
2RecruitingTreatmentExtraskeletal Myxoid Chondrosarcoma / Solitary Fibrous Tumor1
2RecruitingTreatmentHemangiosarcoma1
2RecruitingTreatmentLeiomyosarcomas1
2RecruitingTreatmentMalignant Solid Neoplasms1
2RecruitingTreatmentMetastatic Renal Cell Carcinoma1
2RecruitingTreatmentProgressive Desmoids Tumors1
2RecruitingTreatmentRefractory Pediatric AML / Refractory Pediatric Solid Tumors / Relapsed Pediatric AML / Relapsed Pediatric Solid Tumors1
2RecruitingTreatmentSarcomas / Soft Tissue Sarcoma (STS)1
2RecruitingTreatmentSoft Tissue Sarcoma (STS)1
2RecruitingTreatmentSoft-Tissue Sarcoma1
2RecruitingTreatmentThyroid Carcinoma1
2RecruitingTreatmentTumors, Solid1
2TerminatedBasic ScienceCancer of the Ovary / Cancer, Breast / Cervical Cancers / Gastrointestinal Cancers / Glioblastomas / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancer Small Cell Lung Cancer (SCLC) / Malignant Neoplasm of Pancreas / Melanoma / Renal Cell Adenocarcinoma / Soft Tissue Sarcoma (STS)1
2TerminatedTreatmentBladder Cancers1
2TerminatedTreatmentDermatofibrosarcomas of DARIER FERRAND(DFSP)1
2TerminatedTreatmentEstrogen Receptor-Positive Breast Cancer / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast / Male Breast Cancer / Recurrent Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer1
2TerminatedTreatmentExtra-Adrenal Paraganglioma / Metastatic Adrenal Gland Pheochromocytoma / Paraganglioma / Recurrent Adrenal Gland Pheochromocytoma1
2TerminatedTreatmentHereditary Haemorrhagic Telangiectasia (HHT)1
2TerminatedTreatmentLocally Advanced Renal Cell Carcinoma / Metastatic Renal Cell Carcinoma1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2TerminatedTreatmentMalignant Neoplasm of Pancreas1
2TerminatedTreatmentMetastatic Alveolar Soft Part Sarcoma1
2TerminatedTreatmentMetastatic Bone Sarcomas / Sarcoma, Osteogenic1
2TerminatedTreatmentPenile Squamous Cell Carcinoma Stage IV1
2TerminatedTreatmentProstate Cancer1
2TerminatedTreatmentRenal Cell Adenocarcinoma1
2TerminatedTreatmentSarcomas1
2Unknown StatusTreatmentAdvanced Gastric Cancer1
2Unknown StatusTreatmentAdverse Drug Events / Renal Cell Adenocarcinoma / Self Efficacy1
2Unknown StatusTreatmentBladder (Urothelial, Transitional Cell) Cancer / Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable / Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy) / Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) / Bladder Cancers1
2Unknown StatusTreatmentGastrointestinal Stromal Tumors (GISTs)1
2Unknown StatusTreatmentGerm Cell Tumors / Measurable Disease / Relapse or Progression After 2 or 3 Chemotherapy Regimens / Relapse or Progression After High-dose Chemotherapy1
2Unknown StatusTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
2Unknown StatusTreatmentMelanoma1
2Unknown StatusTreatmentMetastatic Renal Cell Carcinoma1
2Unknown StatusTreatmentRelapsed or Metastatic Uterine Leiomyosarcomas or Carcinosarcomas1
2WithdrawnTreatmentCervical Cancers1
2WithdrawnTreatmentGastrointestinal Stromal Tumors1
2WithdrawnTreatmentHormone-receptors Positive Breast Cancer1
2WithdrawnTreatmentSoft Tissue Sarcoma (STS)1
2WithdrawnTreatmentUterine Leiomyosarcoma1
2, 3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2, 3RecruitingTreatmentAdult Fibrosarcoma / Alveolar Soft Part Sarcoma (ASPS) / Angiomatoid Fibrous Histiocytoma / Atypical Fibroxanthoma / Chondrosarcoma, Mesenchymal / Clear Cell Sarcoma of Soft Tissue / Epithelioid Malignant Peripheral Nerve Sheath Tumor / Epithelioid Sarcoma / Extraskeletal Myxoid Chondrosarcoma / Extraskeletal osteosarcomas / Fibrohistiocytic Neoplasm / Glomus Tumor of the Skin / Inflammatory Myofibroblastic Tumors / Intimal Sarcoma / Leiomyosarcomas / Liposarcoma / Low Grade Fibromyxoid Sarcoma / Low Grade Myofibroblastic Sarcoma / Malignant Cutaneous Granular Cell Tumor / Malignant Peripheral Nerve Sheath Tumour (MPNST) / Malignant Triton Tumor / Myxofibrosarcoma / Myxoid Chondrosarcoma / Myxoinflammatory Fibroblastic Sarcoma / Nerve Sheath Neoplasm / PEComa / Pericytic Neoplasm / Plexiform Fibrohistiocytic Tumor / Sclerosing Epithelioid Fibrosarcoma / Stage IB Soft Tissue Sarcoma / Stage IB Soft Tissue Sarcoma AJCC v7 / Stage IIB Soft Tissue Sarcoma / Stage IIB Soft Tissue Sarcoma AJCC v7 / Stage III Soft Tissue Sarcoma / Stage III Soft Tissue Sarcoma AJCC v7 / Stage IV Soft Tissue Sarcoma / Stage IV Soft Tissue Sarcoma AJCC v7 / Synovial Sarcoma / Undifferentiated (Embryonal) Sarcoma / Undifferentiated High Grade Pleomorphic Sarcoma of Bone1
2, 3TerminatedTreatmentLung Cancers1
3Active Not RecruitingTreatmentCancers1
3Active Not RecruitingTreatmentClear Cell Renal Cell Carcinoma / No Evidence of Disease / Renal Cell Carcinoma Recurrent / Stage IV Renal Cell Cancer / Stage IV Renal Cell Cancer AJCC V71
3Active Not RecruitingTreatmentLocally Advanced or Metastatic Renal Cell Carcinoma / Renal Cell Adenocarcinoma1
3Active Not RecruitingTreatmentRenal Cell Adenocarcinoma1
3CompletedTreatmentMetastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma1
3CompletedTreatmentNeoplasms, Ovarian1
3CompletedTreatmentRenal Cell Adenocarcinoma4
3CompletedTreatmentSoft Tissue Sarcoma (STS)1
3RecruitingTreatmentAdvanced Angiosarcoma1
3RecruitingTreatmentRenal Cell Adenocarcinoma1
4CompletedTreatmentCancers1
4CompletedTreatmentClear-cell Metastatic Renal Cell Carcinoma / Locally Advanced and/or Metastatic Renal Cell Carcinoma / Renal Cell Adenocarcinoma1
4RecruitingOtherMetastatic Renal Cell Cancer1
Not AvailableActive Not RecruitingNot AvailableMetastatic Renal Cell Carcinoma1
Not AvailableActive Not RecruitingDiagnosticAdvanced Solid Tumors / Cancers1
Not AvailableActive Not RecruitingTreatmentStage IIA Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
Not AvailableCompletedNot AvailableMetastatic Renal Cell Carcinoma1
Not AvailableCompletedNot AvailableRenal Cell Adenocarcinoma3
Not AvailableCompletedNot AvailableSoft Tissue Sarcoma (STS)1
Not AvailableCompletedDiagnosticClear Cell Renal Cell Carcinoma / Renal Cell Cancer, Recurrent / Stage IV Renal Cell Cancer1
Not AvailableNot Yet RecruitingTreatmentRefractory Solid Tumors1
Not AvailableRecruitingTreatmentRefractory Solid Tumors1
Not AvailableRecruitingTreatmentRenal Cancers1
Not AvailableWithdrawnTreatmentClear Cell Renal Cell Carcinoma / Renal Cell Adenocarcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral200 mg
TabletOral400 mg
Tablet, film coatedOral200 mg
Tablet, film coatedOral200 mg/1
Tablet, film coatedOral400 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7262203No2001-12-192021-12-19Us
US8114885No2001-12-192021-12-19Us
US7105530No2003-10-192023-10-19Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0433 mg/mLALOGPS
logP3.59ALOGPS
logP3.55ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)10.41ChemAxon
pKa (Strongest Basic)5.07ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area119.03 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity132.18 m3·mol-1ChemAxon
Polarizability45.41 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8788
Caco-2 permeable+0.5
P-glycoprotein substrateNon-substrate0.8307
P-glycoprotein inhibitor INon-inhibitor0.8126
P-glycoprotein inhibitor IIInhibitor0.5
Renal organic cation transporterNon-inhibitor0.8152
CYP450 2C9 substrateNon-substrate0.7797
CYP450 2D6 substrateNon-substrate0.8008
CYP450 3A4 substrateNon-substrate0.6024
CYP450 1A2 substrateNon-inhibitor0.5
CYP450 2C9 inhibitorNon-inhibitor0.5065
CYP450 2D6 inhibitorNon-inhibitor0.7779
CYP450 2C19 inhibitorNon-inhibitor0.6811
CYP450 3A4 inhibitorNon-inhibitor0.5385
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5668
Ames testNon AMES toxic0.6543
CarcinogenicityNon-carcinogens0.8567
BiodegradationNot ready biodegradable0.9935
Rat acute toxicity2.3961 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9219
hERG inhibition (predictor II)Non-inhibitor0.7129
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-052r-0118900000-097bcfa914e959e3d51a
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-0910000000-fd84ad14c383d8fa623f

Taxonomy

Description
This compound belongs to the class of organic compounds known as alkyldiarylamines. These are tertiary alkylarylamines having two aryl and one alkyl groups attached to the amino group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
Alkyldiarylamines
Alternative Parents
Benzenesulfonamides / Benzenesulfonyl compounds / Indazoles / Aniline and substituted anilines / Toluenes / Aminopyrimidines and derivatives / Organosulfonamides / Imidolactams / Heteroaromatic compounds / Pyrazoles
show 6 more
Substituents
Alkyldiarylamine / Benzenesulfonamide / Benzenesulfonyl group / Benzopyrazole / Indazole / Aniline or substituted anilines / Aminopyrimidine / Toluene / Monocyclic benzene moiety / Pyrimidine
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
aminopyrimidine, sulfonamide, indazoles (CHEBI:71219)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Vegf-b-activated receptor activity
Specific Function
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell ...
Gene Name
FLT1
Uniprot ID
P17948
Uniprot Name
Vascular endothelial growth factor receptor 1
Molecular Weight
150767.185 Da
References
  1. Sonpavde G, Hutson TE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007 Mar;9(2):115-9. [PubMed:17288876]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Vascular endothelial growth factor-activated receptor activity
Specific Function
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and ...
Gene Name
KDR
Uniprot ID
P35968
Uniprot Name
Vascular endothelial growth factor receptor 2
Molecular Weight
151525.555 Da
References
  1. Sonpavde G, Hutson TE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007 Mar;9(2):115-9. [PubMed:17288876]
Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Vascular endothelial growth factor-activated receptor activity
Specific Function
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardi...
Gene Name
FLT4
Uniprot ID
P35916
Uniprot Name
Vascular endothelial growth factor receptor 3
Molecular Weight
152755.94 Da
References
  1. Sonpavde G, Hutson TE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007 Mar;9(2):115-9. [PubMed:17288876]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Vascular endothelial growth factor-activated receptor activity
Specific Function
Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chem...
Gene Name
PDGFRA
Uniprot ID
P16234
Uniprot Name
Platelet-derived growth factor receptor alpha
Molecular Weight
122668.46 Da
References
  1. Sonpavde G, Hutson TE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007 Mar;9(2):115-9. [PubMed:17288876]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Vascular endothelial growth factor binding
Specific Function
Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic...
Gene Name
PDGFRB
Uniprot ID
P09619
Uniprot Name
Platelet-derived growth factor receptor beta
Molecular Weight
123966.895 Da
References
  1. Sonpavde G, Hutson TE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007 Mar;9(2):115-9. [PubMed:17288876]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transmembrane receptor protein tyrosine kinase activity
Specific Function
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell main...
Gene Name
KIT
Uniprot ID
P10721
Uniprot Name
Mast/stem cell growth factor receptor Kit
Molecular Weight
109863.655 Da
References
  1. Sonpavde G, Hutson TE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007 Mar;9(2):115-9. [PubMed:17288876]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Protein tyrosine kinase activity
Specific Function
Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an...
Gene Name
FGFR3
Uniprot ID
P22607
Uniprot Name
Fibroblast growth factor receptor 3
Molecular Weight
87708.905 Da
References
  1. Deeks ED: Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000. [PubMed:23072642]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Non-membrane spanning protein tyrosine kinase activity
Specific Function
Tyrosine kinase that plays an essential role in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-c...
Gene Name
ITK
Uniprot ID
Q08881
Uniprot Name
Tyrosine-protein kinase ITK/TSK
Molecular Weight
71830.405 Da
References
  1. Deeks ED: Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000. [PubMed:23072642]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
S100 protein binding
Specific Function
Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.
Gene Name
FGF1
Uniprot ID
P05230
Uniprot Name
Fibroblast growth factor 1
Molecular Weight
17459.58 Da
References
  1. Deeks ED: Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000. [PubMed:23072642]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Signaling adaptor activity
Specific Function
Links T-cell receptor activation signal to phospholipase C-gamma-1, GRB2 and phosphatidylinositol 3-kinase.
Gene Name
SH2B3
Uniprot ID
Q9UQQ2
Uniprot Name
SH2B adapter protein 3
Molecular Weight
63224.45 Da
References
  1. Deeks ED: Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000. [PubMed:23072642]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Keisner SV, Shah SR: Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011 Mar 5;71(4):443-54. doi: 10.2165/11588960-000000000-00000. [PubMed:21395357]
  2. Goh BC, Reddy NJ, Dandamudi UB, Laubscher KH, Peckham T, Hodge JP, Suttle AB, Arumugham T, Xu Y, Xu CF, Lager J, Dar MM, Lewis LD: An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther. 2010 Nov;88(5):652-9. doi: 10.1038/clpt.2010.158. Epub 2010 Sep 29. [PubMed:20881954]
  3. Verweij J, Sleijfer S: Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35. doi: 10.1517/14656566.2013.780030. Epub 2013 Mar 14. [PubMed:23488774]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Keisner SV, Shah SR: Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011 Mar 5;71(4):443-54. doi: 10.2165/11588960-000000000-00000. [PubMed:21395357]
  2. Goh BC, Reddy NJ, Dandamudi UB, Laubscher KH, Peckham T, Hodge JP, Suttle AB, Arumugham T, Xu Y, Xu CF, Lager J, Dar MM, Lewis LD: An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther. 2010 Nov;88(5):652-9. doi: 10.1038/clpt.2010.158. Epub 2010 Sep 29. [PubMed:20881954]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Keisner SV, Shah SR: Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011 Mar 5;71(4):443-54. doi: 10.2165/11588960-000000000-00000. [PubMed:21395357]
  2. Verweij J, Sleijfer S: Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35. doi: 10.1517/14656566.2013.780030. Epub 2013 Mar 14. [PubMed:23488774]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Verweij J, Sleijfer S: Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35. doi: 10.1517/14656566.2013.780030. Epub 2013 Mar 14. [PubMed:23488774]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Deng Y, Sychterz C, Suttle AB, Dar MM, Bershas D, Negash K, Qian Y, Chen EP, Gorycki PD, Ho MY: Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013 May;43(5):443-53. doi: 10.3109/00498254.2012.734642. Epub 2012 Nov 16. [PubMed:23548165]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Deng Y, Sychterz C, Suttle AB, Dar MM, Bershas D, Negash K, Qian Y, Chen EP, Gorycki PD, Ho MY: Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013 May;43(5):443-53. doi: 10.3109/00498254.2012.734642. Epub 2012 Nov 16. [PubMed:23548165]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Deeks ED: Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000. [PubMed:23072642]
  2. Hu S, Mathijssen RH, de Bruijn P, Baker SD, Sparreboom A: Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Br J Cancer. 2014 Feb 18;110(4):894-8. doi: 10.1038/bjc.2013.811. Epub 2014 Jan 7. [PubMed:24398510]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Deeks ED: Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000. [PubMed:23072642]

Drug created on March 19, 2008 10:38 / Updated on August 15, 2018 09:53